Hirokazu Iso

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Real-World Survival Over 25 Years in Extensive-Stage Small-Cell Lung Cancer: The Impact of Immune Checkpoint Inhibitors.

Real-World Survival Over 25 Years in Extensive-Stage Small-Cell Lung Cancer: The Impact of Immune Checkpoint Inhibitors.

Journal: Thoracic cancer

Published: February 16, 2026

Prognostic value of serum CYFRA21-1 in locally advanced non-small cell lung cancer undergoing durvalumab consolidation therapy after chemoradiotherapy.

Prognostic value of serum CYFRA21-1 in locally advanced non-small cell lung cancer undergoing durvalumab consolidation therapy after chemoradiotherapy.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: January 17, 2026

Prognostic impact of HNF4α expression in TTF-1-negative non-squamous NSCLC treated with immune checkpoint inhibitor.

Prognostic impact of HNF4α expression in TTF-1-negative non-squamous NSCLC treated with immune checkpoint inhibitor.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: April 24, 2025

Impact of immune-related adverse event severity on overall survival in patients with advanced NSCLC receiving immune checkpoint inhibitors therapy, with a focus on combination regimens.

Impact of immune-related adverse event severity on overall survival in patients with advanced NSCLC receiving immune checkpoint inhibitors therapy, with a focus on combination regimens.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: January 08, 2025

Efficacy and safety of pleurodesis for lung cancer patients with interstitial lung disease.

Efficacy and safety of pleurodesis for lung cancer patients with interstitial lung disease.

Journal: Journal of thoracic disease

Published: September 18, 2024

Clinical Impact of Osimertinib Dose Reduction in the First-Line Setting on EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Retrospective Monocentric Study.

Clinical Impact of Osimertinib Dose Reduction in the First-Line Setting on EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Retrospective Monocentric Study.

Journal: OncoTargets and therapy

Published: September 13, 2024

Histopathologic pattern and molecular risk stratification are associated with prognosis in patients with stage IB lung adenocarcinoma.

Histopathologic pattern and molecular risk stratification are associated with prognosis in patients with stage IB lung adenocarcinoma.

Journal: Translational lung cancer research

Published: June 13, 2024

Intralobar pulmonary sequestration presenting as multiple nodular pulmonary lesions and focal emphysema.

Intralobar pulmonary sequestration presenting as multiple nodular pulmonary lesions and focal emphysema.

Journal: Respirology case reports

Published: November 17, 2023

Thyroid transcription factor-1 (TTF-1) expression and the efficacy of combination therapy with immune checkpoint inhibitors and cytotoxic chemotherapy in non-squamous non-small cell lung cancer.

Thyroid transcription factor-1 (TTF-1) expression and the efficacy of combination therapy with immune checkpoint inhibitors and cytotoxic chemotherapy in non-squamous non-small cell lung cancer.

Journal: Translational lung cancer research

Published: May 21, 2023

Development of eosinophilic pneumonia from eosinophilic bronchiolitis without asthma: A case report.

Development of eosinophilic pneumonia from eosinophilic bronchiolitis without asthma: A case report.

Journal: Respiratory medicine case reports

Published: April 03, 2023

A remarkable response to combination chemotherapy with nivolumab and ipilimumab in a patient with primary pulmonary choriocarcinoma: a case report.

A remarkable response to combination chemotherapy with nivolumab and ipilimumab in a patient with primary pulmonary choriocarcinoma: a case report.

Journal: Translational cancer research

Published: February 18, 2023

Remarkable Clinical Response of ALK-Rearranged/TP53-Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report.

Remarkable Clinical Response of ALK-Rearranged/TP53-Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report.

Journal: OncoTargets and therapy

Published: January 12, 2023

Showing 1-12 of 12

Last Updated: 09/26/2026